Abstract | BACKGROUND: OBJECTIVE: To characterize long-term safety and efficacy of ozanimod. METHODS: Patients with relapsing MS who completed a phase 1‒3 ozanimod trial were eligible for an open-label extension study (DAYBREAK) of ozanimod 0.92 mg/d. DAYBREAK began 16 October 2015; cutoff for this interim analysis was 2 February 2021. RESULTS: This analysis included 2494 participants with mean 46.8 (SD 11.9; range 0.033‒62.7) months of ozanimod exposure in DAYBREAK. During DAYBREAK, 2143 patients (85.9%) had treatment-emergent adverse events (TEAEs; similar in nature to those in the parent trials), 298 (11.9%) had a serious TEAE, and 75 (3.0%) discontinued treatment due to TEAEs. Serious infections (2.8%), herpes zoster infections (1.7%), confirmed macular edema cases (0.2%), and cardiac TEAEs (2.8%) were infrequent. Adjusted annualized relapse rate was 0.103 (95% confidence interval, 0.086‒0.123). Over 48 months, 71% of patients remained relapse free. Adjusted mean numbers of new/enlarging T2 lesions/scan and gadolinium-enhancing lesions were low and similar across parent trial treatment subgroups. CONCLUSIONS: This long-term extension of ozanimod trials confirmed a favorable safety/tolerability profile and sustained benefit on clinical and magnetic resonance imaging measures of disease activity.
|
Authors | Bruce Ac Cree, Krzysztof W Selmaj, Lawrence Steinman, Giancarlo Comi, Amit Bar-Or, Douglas L Arnold, Hans-Peter Hartung, Xavier Montalbán, Eva K Havrdová, James K Sheffield, Neil Minton, Chun-Yen Cheng, Diego Silva, Ludwig Kappos, Jeffrey A Cohen |
Journal | Multiple sclerosis (Houndmills, Basingstoke, England)
(Mult Scler)
Vol. 28
Issue 12
Pg. 1944-1962
(10 2022)
ISSN: 1477-0970 [Electronic] England |
PMID | 35765217
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Indans
- Oxadiazoles
- Sphingosine-1-Phosphate Receptors
- ozanimod
|
Topics |
- Follow-Up Studies
- Humans
- Indans
(adverse effects)
- Multiple Sclerosis, Relapsing-Remitting
(drug therapy)
- Oxadiazoles
(adverse effects)
- Recurrence
- Sphingosine-1-Phosphate Receptors
|